XML 79 R57.htm IDEA: XBRL DOCUMENT v3.25.1
Research and Development Collaborations (Details)
1 Months Ended 12 Months Ended
Sep. 30, 2016
USD ($)
program
Jun. 30, 2003
USD ($)
Dec. 31, 2024
USD ($)
product
Dec. 31, 2023
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenues     $ 10,908,000 $ 10,023,000
Accounts receivable     $ 3,349,000 2,794,000
Number of programs licensed | program 4      
Royalty fees receivable (as a percent)     10.00%  
Genentech, Inc.        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Amount received for specified clinical development and regulatory objectives     $ 59,000,000.0  
Percentage of royalty rate decrease   2.00%    
Accounts receivable     3,300,000 2,700,000
Genentech, Inc. | Royalties        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenues     $ 10,900,000 $ 9,900,000
Genentech, Inc. | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Eligible to receive contingent cash milestone payments (up to)   $ 115,000,000.0    
Percentage of royalty on net sales   7.50%    
Genentech, Inc. | Minimum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Percentage of royalty on net sales   5.00%    
Aurigene Discovery Technologies Limited        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Waived payment of milestone and other payments (up to) $ 24,500,000      
Number of products required to commercialize | product     1  
Aurigene Discovery Technologies Limited | Third and Fourth Programs        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Additional funding $ 2,000,000.0      
Aurigene Discovery Technologies Limited | IRAK4, PD1/VISTA,PD1/TIM3 Program        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Waived payment of milestone and other payments (up to)     $ 42,500,000